Allergy & Immunology

Resource Center

FDA Alerts

FDA Alert

FDA Approves Epinephrine Nasal Spray for Allergic Reactions, Anaphylaxis

08/19/2024

Anthony Calabro, MA

The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.

08/19/2024

Research Summaries

FDA Alert

FDA Approves Epinephrine Nasal Spray for Allergic Reactions, Anaphylaxis

08/19/2024

Anthony Calabro, MA

The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.

08/19/2024

Research summary

Research summary

Clinical Practice Guidelines on Immunotherapy Recommendations for Inhalant Allergy

07/11/2024

Jessica Ganga

The American Academy of Otolaryngology-Head and Neck Surgery Foundation released a set of guidelines that outline evidence-based recommendations on the use of immunotherapy for inhalant allergy for...

07/11/2024

Roundtable Wrap-Up

Managing Patients With Atopic Dermatitis—Key Talking Points, Action Plans, and Shared-decision Making

09/05/2023

In this Roundtable Wrap-Up, we offer an abbreviated version of the roundtable discussion on the evaluation, treatment, and management of patients with moderate-to-severe atopic dermatitis.

09/05/2023

Research Summary

Vitamin D Does Not Effectively Help Asthma Symptom Management

02/16/2023

The researchers re-evaluated the effects of vitamin D on asthma exacerbation.

02/16/2023

treatment

Exacerbations Increased After Discontinuing Long-term Use of Mepolizumab for Severe Eosinophilic Asthma

08/19/2022

While the long-term safety and efficacy of mepolizumab have been studied, gaps in the literature have remained on the clinical impact of stopping mepolizumab after long-term use. Researchers examined how...

08/19/2022

September 2024

Current Issue

September 2024

Volume 64

Issue 9